ArticleNational science review2026
Amine oxide lipid nanoparticles for delivery of cyclic dinucleotides.
Article in National science review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical potential of cyclic dinucleotides (CDNs) as potent agonists of the stimulator of interferon gene (STING) has been hampered by the lack of robust delivery systems. While lipid nanoparticles (LNPs) excel with large nucleic acids, they are unsuitable for delivering small, zwitterionic and highly hydrophilic CDNs. Here, we find that the tertiary amine oxide lipid (AOL) promotes stable encapsulation of CDNs into LNP through enhanced hydrogen bonding and electrostatic interactions, resulting in ultra-high encapsulation efficiency of 86.8%. Compared to cationic liposomes, AOL-incorporating LNP exhibits superior tumor penetration and cytosolic cargo delivery, eliciting broad and potent intratumoral STING activation. In line with growing emphasis on combination therapy in oncology, we further incorporate lipidated mitoxantrone in the LNP as an inducer of immunogenic cell death to enhance tumor antigen presentation and STING-driven immunotherapy. The obtained LNP provokes potent immunostimulatory and antitumor effects in multiple challenging animal models, including triple-negative breast cancer, pancreatic cancer and melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.